Kochenderfer et al. used donor-derived CD19-28z-CAR-T cells to treat 10 patients (4 with chronic lymphocytic leukemia (CLL) and 6 with lymphoma, including 2 with diffuse large B cell lymphoma (DLBCL) and 4 with mantle cell lymphoma (MCL)) with CD19+ B cell malignancy that persisted despite allo-HSCT and at least one standard DLI. Here, CD19 is linked to diffuse large B-cell lymphoma.